摘要：In March 2013 the U.S. spent a staggering $463 million for 2 million new smallpox doses in defense of a potential bioterrorist attack. This new drug, Arestyvr, made by New York-based Siga Technologies, is an antiviral pill that treats infected victims after the smallpox vaccine is too late to be administered. The purchase of Arestyvr was wasteful spending for two reasons: smallpox is an improbable bioterrorism agent and Arestyvr’s worth is questionable
Loading...
